Kasprowicz Victoria, Isa Adiba, Tolfvenstam Thomas, Jeffery Katie, Bowness Paul, Klenerman Paul
Partners AIDS Research Center, Massachusetts General Hospital, Harvard Medical School, 149 13th Street, Charlestown, MA 02129, USA.
J Virol. 2006 Nov;80(22):11209-17. doi: 10.1128/JVI.01173-06. Epub 2006 Aug 30.
The evolution of peptide-specific CD4(+) T-cell responses to acute viral infections of humans is poorly understood. We analyzed the response to parvovirus B19 (B19), a ubiquitous and clinically significant pathogen with a compact and conserved genome. The magnitude and breadth of the CD4(+) T-cell response to the two B19 capsid proteins were investigated using a set of overlapping peptides and gamma interferon-specific enzyme-linked immunospot assays of peripheral blood mononuclear cells (PBMCs) from a cohort of acutely infected individuals who presented with acute arthropathy. These were compared to those for a cohort of B19-specific immunoglobulin M-negative (IgM(-)), IgG(+) remotely infected individuals. Both cohorts of individuals were found to make broad CD4(+) responses. However, while the responses following acute infection were detectable ex vivo, responses in remotely infected individuals were only detected after culture. One epitope (LASEESAFYVLEHSSFQLLG) was consistently targeted by both acutely (10/12) and remotely (6/7) infected individuals. This epitope was DRB1*1501 restricted, and a major histocompatibility complex peptide tetramer stained PBMCs from acutely infected individuals in the range of 0.003 to 0.042% of CD4(+) T cells. Tetramer-positive populations were initially CD62L(lo); unlike the case for B19-specific CD8(+) T-cell responses, however, CD62L was reexpressed at later times, as responses remained stable or declined slowly. This first identification of B19 CD4(+) T-cell epitopes, including a key immunodominant peptide, provides the tools to investigate the breadth, frequency, and functions of cellular responses to this virus in a range of specific clinical settings and gives an important reference point for analysis of peptide-specific CD4(+) T cells during acute and persistent virus infections of humans.
人们对人类急性病毒感染中肽特异性CD4(+) T细胞反应的演变了解甚少。我们分析了对细小病毒B19(B19)的反应,B19是一种普遍存在且具有临床意义的病原体,其基因组紧凑且保守。使用一组重叠肽以及来自一群出现急性关节炎的急性感染个体的外周血单个核细胞(PBMC)的γ干扰素特异性酶联免疫斑点试验,研究了对两种B19衣壳蛋白的CD4(+) T细胞反应的强度和广度。将这些结果与一组B19特异性免疫球蛋白M阴性(IgM(-))、IgG(+)的既往感染个体的结果进行比较。发现两组个体均产生广泛的CD4(+)反应。然而,虽然急性感染后的反应可在体外检测到,但既往感染个体的反应仅在培养后才能检测到。一个表位(LASEESAFYVLEHSSFQLLG)在急性感染个体(10/12)和既往感染个体(6/7)中均持续被靶向。该表位受DRB1*1501限制,一种主要组织相容性复合体肽四聚体对急性感染个体的PBMC进行染色,阳性细胞占CD4(+) T细胞的0.003%至0.042%。四聚体阳性群体最初为CD62L(lo);然而,与B19特异性CD8(+) T细胞反应不同的是,CD62L在后期重新表达,因为反应保持稳定或缓慢下降。首次鉴定出B19 CD4(+) T细胞表位,包括一个关键的免疫显性肽,为在一系列特定临床环境中研究针对该病毒的细胞反应的广度、频率和功能提供了工具,并为分析人类急性和持续性病毒感染期间的肽特异性CD4(+) T细胞提供了重要的参考点。